MDACC Study No:2012-0178 ( NCT No: NCT01358331)
Title:A Phase I Study to Evaluate the Safety, Tolerability and Effectiveness of MK-8353 (formerly SCH 900353)in Subjects with Advanced Tumors
Principal Investigator:Wen-Jen Hwu
Treatment Agent:SCH900353
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if MK-8353 can help to
control colorectal cancer and/or melanoma.

MK-8353 is designed to control an enzyme. If this enzyme is controlled, it may
help stop the growth of cancer cells.

There may be reasons why you are not allowed to take part in this study. The
study doctor or staff will discuss these with you.
Hide details for General InformationGeneral Information

Disease Group:Colorectum; Melanoma
Phase of Study:Phase I
Treatment Agents:SCH900353
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Schering Plough/Merck
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Wen-Jen Hwu
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults